Bio-Rad Laboratories, Inc. BIOB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 251.34% | -30.33% | 107.80% | 141.20% | 13.20% |
| Total Depreciation and Amortization | 2.22% | 7.59% | 10.22% | 9.10% | 8.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -187.94% | 70.09% | -96.42% | -124.04% | -17.27% |
| Change in Net Operating Assets | 270.66% | -3.03% | 109.55% | 143.88% | 52.13% |
| Cash from Operations | -4.76% | -7.79% | -0.95% | 16.92% | 19.30% |
| Capital Expenditure | 10.15% | 14.52% | 4.13% | 4.83% | 6.22% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | 100.00% | 0.00% | -48.98% |
| Cash Acquisitions | 100.50% | 99.68% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -208.02% | -153.51% | 88.35% | 3,415.09% | 78.60% |
| Cash from Investing | -82.80% | -19.33% | -150.26% | -18.41% | -223.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.00% | -25.00% | -66.67% | -25.00% | 45.55% |
| Issuance of Common Stock | -4.43% | -14.86% | -17.22% | -17.71% | -19.52% |
| Repurchase of Common Stock | 71.53% | 60.47% | 19.66% | -44.20% | 27.56% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 101.67% | 101.67% | 101.67% | -- | -4,900.00% |
| Cash from Financing | 77.65% | 66.09% | 27.49% | -29.43% | 20.47% |
| Foreign Exchange rate Adjustments | 257.35% | 181.05% | -295.74% | -283.70% | 8.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 592.14% | 508.61% | -115.79% | -50.35% | 69.61% |